Leucid Bio
- Biotech or pharma, therapeutic R&D
Leucid Bio is a privately held, biotechnology company developing novel, lateral CAR-Ts for the treatment of refractory cancers. The Company's lead candidate is LEU011 – an autologous, lateral CAR-T targeting NKG2D stress ligands.
In January 2025, the Company initiated the Phase 1 AERIAL trial to evaluate the safety and clinical activity of LEU011 following preconditioning chemotherapy in patients with relapsed or refractory solid tumours. Proof-of-concept data from the Phase 1 AERIAL trial are expected by year-end 2025.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}